JP2013227347A5 - - Google Patents
Download PDFInfo
- Publication number
- JP2013227347A5 JP2013227347A5 JP2013165982A JP2013165982A JP2013227347A5 JP 2013227347 A5 JP2013227347 A5 JP 2013227347A5 JP 2013165982 A JP2013165982 A JP 2013165982A JP 2013165982 A JP2013165982 A JP 2013165982A JP 2013227347 A5 JP2013227347 A5 JP 2013227347A5
- Authority
- JP
- Japan
- Prior art keywords
- composition
- pharmaceutically acceptable
- acceptable salt
- compound
- combination
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Withdrawn
Links
- 239000000203 mixture Substances 0.000 claims 13
- 150000003839 salts Chemical class 0.000 claims 9
- 150000001875 compounds Chemical class 0.000 claims 8
- 239000003814 drug Substances 0.000 claims 8
- 229940124597 therapeutic agent Drugs 0.000 claims 8
- 206010028980 Neoplasm Diseases 0.000 claims 6
- 201000011510 cancer Diseases 0.000 claims 6
- GXJABQQUPOEUTA-RDJZCZTQSA-N bortezomib Chemical compound C([C@@H](C(=O)N[C@@H](CC(C)C)B(O)O)NC(=O)C=1N=CC=NC=1)C1=CC=CC=C1 GXJABQQUPOEUTA-RDJZCZTQSA-N 0.000 claims 3
- 229960001467 bortezomib Drugs 0.000 claims 3
- UREBDLICKHMUKA-CXSFZGCWSA-N dexamethasone Chemical compound C1CC2=CC(=O)C=C[C@]2(C)[C@]2(F)[C@@H]1[C@@H]1C[C@@H](C)[C@@](C(=O)CO)(O)[C@@]1(C)C[C@@H]2O UREBDLICKHMUKA-CXSFZGCWSA-N 0.000 claims 3
- 229960003957 dexamethasone Drugs 0.000 claims 3
- UWKQSNNFCGGAFS-XIFFEERXSA-N irinotecan Chemical compound C1=C2C(CC)=C3CN(C(C4=C([C@@](C(=O)OC4)(O)CC)C=4)=O)C=4C3=NC2=CC=C1OC(=O)N(CC1)CCC1N1CCCCC1 UWKQSNNFCGGAFS-XIFFEERXSA-N 0.000 claims 3
- 229960004768 irinotecan Drugs 0.000 claims 3
- DWAFYCQODLXJNR-BNTLRKBRSA-L oxaliplatin Chemical compound O1C(=O)C(=O)O[Pt]11N[C@@H]2CCCC[C@H]2N1 DWAFYCQODLXJNR-BNTLRKBRSA-L 0.000 claims 3
- 229960001756 oxaliplatin Drugs 0.000 claims 3
- AOJJSUZBOXZQNB-TZSSRYMLSA-N Doxorubicin Chemical compound O([C@H]1C[C@@](O)(CC=2C(O)=C3C(=O)C=4C=CC=C(C=4C(=O)C3=C(O)C=21)OC)C(=O)CO)[C@H]1C[C@H](N)[C@H](O)[C@H](C)O1 AOJJSUZBOXZQNB-TZSSRYMLSA-N 0.000 claims 2
- 238000009472 formulation Methods 0.000 claims 2
- 208000032839 leukemia Diseases 0.000 claims 2
- 208000036762 Acute promyelocytic leukaemia Diseases 0.000 claims 1
- 208000000461 Esophageal Neoplasms Diseases 0.000 claims 1
- 206010025323 Lymphomas Diseases 0.000 claims 1
- 208000034578 Multiple myelomas Diseases 0.000 claims 1
- 201000003793 Myelodysplastic syndrome Diseases 0.000 claims 1
- 208000014767 Myeloproliferative disease Diseases 0.000 claims 1
- 206010035226 Plasma cell myeloma Diseases 0.000 claims 1
- 210000000601 blood cell Anatomy 0.000 claims 1
- 210000000988 bone and bone Anatomy 0.000 claims 1
- 201000006491 bone marrow cancer Diseases 0.000 claims 1
- 210000004556 brain Anatomy 0.000 claims 1
- 210000000481 breast Anatomy 0.000 claims 1
- 210000003169 central nervous system Anatomy 0.000 claims 1
- 210000001072 colon Anatomy 0.000 claims 1
- 229960004679 doxorubicin Drugs 0.000 claims 1
- 239000003937 drug carrier Substances 0.000 claims 1
- 210000004696 endometrium Anatomy 0.000 claims 1
- 201000004101 esophageal cancer Diseases 0.000 claims 1
- 210000003238 esophagus Anatomy 0.000 claims 1
- 210000003128 head Anatomy 0.000 claims 1
- 230000002489 hematologic effect Effects 0.000 claims 1
- 210000003734 kidney Anatomy 0.000 claims 1
- 210000004185 liver Anatomy 0.000 claims 1
- 210000004072 lung Anatomy 0.000 claims 1
- 210000001165 lymph node Anatomy 0.000 claims 1
- SGDBTWWWUNNDEQ-LBPRGKRZSA-N melphalan Chemical compound OC(=O)[C@@H](N)CC1=CC=C(N(CCCl)CCCl)C=C1 SGDBTWWWUNNDEQ-LBPRGKRZSA-N 0.000 claims 1
- 229960001924 melphalan Drugs 0.000 claims 1
- 210000003739 neck Anatomy 0.000 claims 1
- 210000001672 ovary Anatomy 0.000 claims 1
- 210000000496 pancreas Anatomy 0.000 claims 1
- 210000002307 prostate Anatomy 0.000 claims 1
- 210000003491 skin Anatomy 0.000 claims 1
- 210000000813 small intestine Anatomy 0.000 claims 1
- 210000000952 spleen Anatomy 0.000 claims 1
- 210000002784 stomach Anatomy 0.000 claims 1
- 230000002195 synergetic effect Effects 0.000 claims 1
- 210000001550 testis Anatomy 0.000 claims 1
- 230000001225 therapeutic effect Effects 0.000 claims 1
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US157507P | 2007-11-02 | 2007-11-02 | |
| US61/001,575 | 2007-11-02 |
Related Parent Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2010532063A Division JP2011502985A (ja) | 2007-11-02 | 2008-10-31 | 有機ヒ素剤を使用する併用療法 |
Related Child Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2014053434A Division JP2014111666A (ja) | 2007-11-02 | 2014-03-17 | 有機ヒ素剤を使用する併用療法 |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| JP2013227347A JP2013227347A (ja) | 2013-11-07 |
| JP2013227347A5 true JP2013227347A5 (https=) | 2014-05-01 |
Family
ID=40626049
Family Applications (3)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2010532063A Pending JP2011502985A (ja) | 2007-11-02 | 2008-10-31 | 有機ヒ素剤を使用する併用療法 |
| JP2013165982A Withdrawn JP2013227347A (ja) | 2007-11-02 | 2013-08-09 | 有機ヒ素剤を使用する併用療法 |
| JP2014053434A Pending JP2014111666A (ja) | 2007-11-02 | 2014-03-17 | 有機ヒ素剤を使用する併用療法 |
Family Applications Before (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2010532063A Pending JP2011502985A (ja) | 2007-11-02 | 2008-10-31 | 有機ヒ素剤を使用する併用療法 |
Family Applications After (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2014053434A Pending JP2014111666A (ja) | 2007-11-02 | 2014-03-17 | 有機ヒ素剤を使用する併用療法 |
Country Status (9)
| Country | Link |
|---|---|
| US (3) | US8252773B2 (https=) |
| EP (1) | EP2209480B1 (https=) |
| JP (3) | JP2011502985A (https=) |
| KR (1) | KR20100100835A (https=) |
| CN (1) | CN101903029B (https=) |
| AU (1) | AU2008325243B2 (https=) |
| CA (1) | CA2704395A1 (https=) |
| ES (1) | ES2392737T3 (https=) |
| WO (1) | WO2009061373A1 (https=) |
Families Citing this family (2)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| ES2532666T3 (es) * | 2005-07-29 | 2015-03-30 | Solasia Pharma K.K. | Compuestos y métodos para el tratamiento del cáncer |
| RU2534606C2 (ru) * | 2008-08-20 | 2014-11-27 | Зайофарм Онколоджи, Инк. | Мышьякорганические соединения и способы лечения рака |
Family Cites Families (13)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US2349729A (en) | 1940-08-24 | 1944-05-23 | Parke Davis & Co | Therapeutic arsenic preparation |
| JP2001519366A (ja) | 1997-10-15 | 2001-10-23 | ポーラクス バイオファーマシュティカルズ，インコーポレーテッド | ヒ素化合物を用いた、原発性および転移性の腫瘍性疾患を治療するための組成物および方法 |
| IL136051A0 (en) | 1997-11-10 | 2001-05-20 | Sloan Kettering Inst Cancer | Process for producing arsenic trioxide formulations and methods for treating cancer using arsenic trioxide or melarsoprol |
| CN1233476A (zh) | 1998-04-24 | 1999-11-03 | 陆道培 | 治疗急性白血病的药物及其制备方法 |
| EP1002537A1 (en) | 1998-10-30 | 2000-05-24 | Assistance Publique, Hopitaux De Paris | Use of melarsoprol for the manufacture of a medicament for treating B-cell lymphoproliferative diseases, such as multiple myeloma |
| US6191123B1 (en) | 1999-03-19 | 2001-02-20 | Parker Hughes Institute | Organic-arsenic compounds |
| EP1328253B1 (en) | 2000-04-26 | 2006-03-22 | Oregon Health Sciences University | Administration of a thiol-based chemoprotectant compound |
| US6911471B2 (en) * | 2002-01-07 | 2005-06-28 | The Texas A&M University System | S-dimethylarsino-thiosuccinic acid s-dimethylarsino-2-thiobenzoic acid s-(dimethylarsino) glutathione as treatments for cancer |
| CN1889943A (zh) * | 2003-12-08 | 2007-01-03 | 美国亚利桑那大学董事会 | 协同抗癌组合物 |
| TW200538149A (en) * | 2004-05-20 | 2005-12-01 | Telik Inc | Sensitization to another anticancer therapy and/or amelioration of a side effect of another anticancer therapy by treatment with a GST-activated anticancer compound |
| TWI411431B (zh) | 2004-07-16 | 2013-10-11 | Texas A & M Univ Sys | 有機砷化合物、其用於治療癌症之用途及包含其之醫藥組成物 |
| ES2532666T3 (es) | 2005-07-29 | 2015-03-30 | Solasia Pharma K.K. | Compuestos y métodos para el tratamiento del cáncer |
| TW200829261A (en) | 2006-09-29 | 2008-07-16 | Ziopharm Oncology Inc | Method for controlling angiogenesis in animals |
-
2008
- 2008-10-31 KR KR1020107011723A patent/KR20100100835A/ko not_active Ceased
- 2008-10-31 CA CA2704395A patent/CA2704395A1/en not_active Abandoned
- 2008-10-31 ES ES08848529T patent/ES2392737T3/es active Active
- 2008-10-31 US US12/740,661 patent/US8252773B2/en not_active Expired - Fee Related
- 2008-10-31 CN CN2008801142801A patent/CN101903029B/zh not_active Expired - Fee Related
- 2008-10-31 WO PCT/US2008/012385 patent/WO2009061373A1/en not_active Ceased
- 2008-10-31 EP EP08848529A patent/EP2209480B1/en not_active Not-in-force
- 2008-10-31 JP JP2010532063A patent/JP2011502985A/ja active Pending
- 2008-10-31 AU AU2008325243A patent/AU2008325243B2/en not_active Ceased
-
2012
- 2012-07-26 US US13/559,036 patent/US20120295861A1/en not_active Abandoned
-
2013
- 2013-03-06 US US13/786,591 patent/US20130261082A1/en not_active Abandoned
- 2013-08-09 JP JP2013165982A patent/JP2013227347A/ja not_active Withdrawn
-
2014
- 2014-03-17 JP JP2014053434A patent/JP2014111666A/ja active Pending
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP2015529234A5 (https=) | ||
| JP2015511609A5 (https=) | ||
| ES2717898T3 (es) | Efecto potenciador para agentes antitumorales | |
| JP2015212268A5 (https=) | ||
| JP2010533206A5 (https=) | ||
| JP2019503365A5 (https=) | ||
| JP2019515908A5 (https=) | ||
| JP2016506916A5 (https=) | ||
| JP2014509659A5 (https=) | ||
| JP2016528162A5 (https=) | ||
| RU2018105655A (ru) | Комбинированная терапия с применением липосомального иринотекана и ингибитора parp для лечения рака | |
| JP2014500295A5 (https=) | ||
| JP2015512398A5 (https=) | ||
| JP2014512356A5 (https=) | ||
| JP2008528671A5 (https=) | ||
| TWI641374B (zh) | 含低用量伊立替康鹽酸鹽水合物之抗腫瘤劑 | |
| JP2012255026A5 (https=) | ||
| JP2015512943A5 (https=) | ||
| JP2020097577A5 (https=) | ||
| JP2008506710A5 (https=) | ||
| JP2014507412A5 (https=) | ||
| JP2014512355A5 (https=) | ||
| JP2012522841A5 (https=) | ||
| JP2011520846A5 (https=) | ||
| RU2013148817A (ru) | Комбинации соединений-ингибиторов акт и мек и способы их применения |